MX340094B - Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. - Google Patents
Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.Info
- Publication number
- MX340094B MX340094B MX2013004960A MX2013004960A MX340094B MX 340094 B MX340094 B MX 340094B MX 2013004960 A MX2013004960 A MX 2013004960A MX 2013004960 A MX2013004960 A MX 2013004960A MX 340094 B MX340094 B MX 340094B
- Authority
- MX
- Mexico
- Prior art keywords
- complement
- complement activation
- individual
- point
- lateral flow
- Prior art date
Links
- 230000024203 complement activation Effects 0.000 title abstract 5
- 230000000295 complement effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000003018 immunoassay Methods 0.000 title abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40929710P | 2010-11-02 | 2010-11-02 | |
| PCT/US2011/058945 WO2012071145A1 (en) | 2010-11-02 | 2011-11-02 | Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004960A MX2013004960A (es) | 2013-12-16 |
| MX340094B true MX340094B (es) | 2016-06-27 |
Family
ID=46146161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004960A MX340094B (es) | 2010-11-02 | 2011-11-02 | Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9182396B2 (enExample) |
| EP (2) | EP3095876A1 (enExample) |
| JP (1) | JP5859557B2 (enExample) |
| AU (2) | AU2011332241B2 (enExample) |
| CA (1) | CA2816423A1 (enExample) |
| ES (1) | ES2564290T3 (enExample) |
| MX (1) | MX340094B (enExample) |
| WO (1) | WO2012071145A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3095876A1 (en) | 2010-11-02 | 2016-11-23 | Kypha, Inc. | Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
| US8865164B2 (en) * | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| US9110030B2 (en) | 2012-06-29 | 2015-08-18 | Daniel A. Kerschensteiner | Colorimetric gelatinase assay |
| ES2695000T3 (es) * | 2013-06-10 | 2018-12-28 | Asahi Kasei Kabushiki Kaisha | Kit de diagnóstico inmunocromatográfico |
| CN106461661A (zh) | 2014-05-02 | 2017-02-22 | Uab研究基金会 | 用于诊断和治疗脑膜炎的方法及组合物 |
| US11029318B2 (en) * | 2015-08-28 | 2021-06-08 | Kypha, Inc. | Methods for predicting and treating patients with increased risk of adverse pregnancy outcome |
| KR102141591B1 (ko) * | 2016-05-13 | 2020-09-14 | 광주과학기술원 | 진단용 키트 |
| US11913951B2 (en) * | 2018-03-26 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | High throughput method for measuring the protease activity of complement C3 convertase |
| EP3581934A1 (en) * | 2018-06-14 | 2019-12-18 | Otto-von-Guericke-Universität Magdeburg | Complement factors for diagnosis of low-grade infections in a human subject |
| WO2021222169A1 (en) * | 2020-04-27 | 2021-11-04 | Zinselmeyer Bernd H | Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2 |
| EP4217744A4 (en) * | 2020-09-28 | 2024-11-06 | Allegheny Singer Research Institute | METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT |
| EP4286850A4 (en) * | 2021-01-26 | 2024-11-27 | Sekisui Medical Co., Ltd. | IMMUNOLOGICAL ASSAY PROCEDURE |
| EP4334719A4 (en) * | 2021-05-07 | 2025-04-16 | Kypha, Inc. | TARGET MEASUREMENT |
| WO2023192436A1 (en) * | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212071A (en) * | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| JPS595958B2 (ja) | 1975-12-30 | 1984-02-08 | トウキヨウケイソウ カブシキガイシヤ | 変量測定・伝送装置 |
| EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| SE452067B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Reagens for och sett vid immunkemisk bestemning av c3a |
| IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification |
| WO2003062824A1 (en) * | 2002-01-23 | 2003-07-31 | Boditech Inc. | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| WO2004093636A2 (en) * | 2003-04-17 | 2004-11-04 | Rauno Joks | PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY |
| KR20060015646A (ko) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | 면역, 혈액 및 염증성 질환의 모니터링 방법 |
| US20070224703A1 (en) * | 2003-09-29 | 2007-09-27 | Fariba Nayeri | Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids |
| US20050255533A1 (en) * | 2004-02-10 | 2005-11-17 | Brendan Bioscience, Llc | Comprehensive food allergy test |
| US20060292700A1 (en) * | 2005-06-22 | 2006-12-28 | Naishu Wang | Diffused interrupted lateral flow immunoassay device and method |
| WO2006124888A2 (en) * | 2005-05-16 | 2006-11-23 | Brendan Bioscience, Llc | Detection of antigen specific immunocomplexes |
| US7910381B2 (en) | 2005-10-13 | 2011-03-22 | BioAssay Works | Immuno gold lateral flow assay |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| EP2384367A4 (en) * | 2008-12-30 | 2013-07-10 | Janssen Biotech Inc | SERUM MARKERS TO PREDICT THE CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH MORBUS BECHTEREW |
| US9291622B2 (en) * | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| EP3095876A1 (en) | 2010-11-02 | 2016-11-23 | Kypha, Inc. | Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders |
-
2011
- 2011-11-02 EP EP15199549.5A patent/EP3095876A1/en not_active Withdrawn
- 2011-11-02 AU AU2011332241A patent/AU2011332241B2/en active Active
- 2011-11-02 MX MX2013004960A patent/MX340094B/es active IP Right Grant
- 2011-11-02 JP JP2013537784A patent/JP5859557B2/ja active Active
- 2011-11-02 US US13/287,432 patent/US9182396B2/en active Active
- 2011-11-02 WO PCT/US2011/058945 patent/WO2012071145A1/en not_active Ceased
- 2011-11-02 ES ES11842681.6T patent/ES2564290T3/es active Active
- 2011-11-02 CA CA2816423A patent/CA2816423A1/en not_active Abandoned
- 2011-11-02 EP EP11842681.6A patent/EP2635702B1/en active Active
-
2015
- 2015-08-13 US US14/825,437 patent/US9939446B2/en active Active
-
2016
- 2016-02-05 AU AU2016200772A patent/AU2016200772B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150346211A1 (en) | 2015-12-03 |
| US9182396B2 (en) | 2015-11-10 |
| AU2016200772B2 (en) | 2018-02-01 |
| EP3095876A1 (en) | 2016-11-23 |
| EP2635702B1 (en) | 2016-02-03 |
| AU2011332241A1 (en) | 2013-05-23 |
| MX2013004960A (es) | 2013-12-16 |
| JP5859557B2 (ja) | 2016-02-10 |
| JP2014502347A (ja) | 2014-01-30 |
| AU2011332241A2 (en) | 2013-06-13 |
| AU2016200772A1 (en) | 2016-02-25 |
| AU2011332241B2 (en) | 2015-11-26 |
| EP2635702A4 (en) | 2014-04-02 |
| WO2012071145A1 (en) | 2012-05-31 |
| US20120141457A1 (en) | 2012-06-07 |
| US9939446B2 (en) | 2018-04-10 |
| ES2564290T3 (es) | 2016-03-21 |
| EP2635702A1 (en) | 2013-09-11 |
| CA2816423A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013004960A (es) | Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de transtornos asociados con el complemento. | |
| MX2016006252A (es) | Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono. | |
| GB2504022A (en) | Surface preparation | |
| MX2014001426A (es) | Metodos para monitorear fluidos dentro de o producidos desde una formacion subterranea utilizando dispositivos optico-analiticos. | |
| WO2015102726A3 (en) | A microfluidic device for real-time clinical monitoring and quantitative assessment of whole blood coagulation | |
| PH12013502340A1 (en) | Biomarkers for hedgehog inhibitor therapy | |
| GB2484631A (en) | System and methods for monitoring a well | |
| MX341261B (es) | Sistemas y metodos para monitorear procesos quimicos. | |
| MX2023002021A (es) | Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune. | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| HK1208256A1 (en) | Microfluidic pump | |
| GB2544922A (en) | Methods and systems for simulating a hydrocarbon field using a multi-point well connection method | |
| MY190476A (en) | Steady state fluid flow verification for sample takeoff | |
| IN2014KN02809A (enExample) | ||
| GB201113992D0 (en) | Device | |
| GB2538374A (en) | Determining formation gas composition during well drilling | |
| WO2012068040A3 (en) | Detection of vestibular disorders based on vestibular noise | |
| WO2014141293A3 (en) | A method and system for estimation of blood anylates | |
| EA201791707A1 (ru) | Переносное устройство для оперативного измерения концентрации сероводорода в выходящем газовом потоке | |
| UA78641U (ru) | Способ прогнозирования тяжести больных острым панкреатитом | |
| MX2018016216A (es) | Deteccion de analitos de flujo lateral. | |
| WO2014145797A3 (en) | Method for treating eclampsia and preeclampsia | |
| WO2013088140A3 (en) | Tenascin-c and use thereof in rheumatoid arthritis | |
| FR2991771B1 (fr) | Dispositif de controle de la coagulation d'un fluide, notamment du lait, et procede de controle associe | |
| WO2014009055A9 (en) | Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |